Effect of on-line hemodiafiltration with endogenous reinfusion (HFR) on the calcium-phosphorus metabolism: Medium-term effects

International Journal of Artificial Organs

Volumn 29, Issue 11, 2006, Pages 1042-1052

  Bolasco, Piergiorgio G ^a   Chezzi, P M ^b   Ferrara, R ^c   Maxia, M ^d   Pinna, M ^e   Logias, F ^f   Cogoni, G ^g   Cadinu, F ^h   Ghisu, T ⁱ   Contu, B ^j   Casu, D ^k   Passaghe, M ^l   Pilloni, A ^m   Ganadu, M ⁿ   Gazzanelli, L ^o  

^a Azienda USL n 8   (Italy)

^b A O S Croce e Carle   (Italy)

^c SS Trinit Hospital   (Italy)

^d Casa di Cura Polispecialistica Sant'Elena   (Italy)

^e SS Annunziata Hospital   (Italy)

^f Sorgono and Ospedale S Giuseppe   (Italy)

^g San Martino Hospital   (Italy)

^h SAN FRANCESCO HOSPITAL   (Italy)

ⁱ Ospedale Civile   (Italy)

^j Azienda USL n 4   (Italy)

^k Civil Hospital   (Italy)

^l Ospedale Civile   (Italy)

^m Ospedale NS di Bonaria   (Italy)

ⁿ Ospedale ASegni   (Italy)

^o Ospedale P Merlo   (Italy)

more..

Author keywords

Bone metabolism; Cytokines; Dialysis microinflammation; HRF; On line hemodiafiltration with endogenous reinfusion

Indexed keywords

BONE; CALCIUM; CALCIUM PHOSPHATE; CHELATION; METABOLISM; MULTIVARIANT ANALYSIS; NUTRITION; PHOSPHATASES; PHOSPHORUS;

ALKALINE PHOSPHATASE; BONE METABOLISM; BONE TURNOVER; CYTOKINES; DIALYSIS MICROINFLAMMATION; HAEMODIALYSIS; HEMODIAFILTRATION; HRF; ON-LINE HEMODIAFILTRATION WITH ENDOGENOUS REINFUSION; PHOSPHORUS METABOLISM;

DIALYSIS;

ALKALINE PHOSPHATASE; ALUMINUM HYDROXIDE; BETA 2 MICROGLOBULIN; CALCITRIOL; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; CREACTIVE PROTEIN; CYTOKINE; ISOENZYME; MAGNESIUM CARBONATE; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; PHOSPHORUS; SEVELAMER; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; AGED; ARTICLE; BONE METABOLISM; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMODIAFILTRATION; HEMOFILTRATION; HORMONE DETERMINATION; HUMAN; HYPERPHOSPHATEMIA; INTERMETHOD COMPARISON; MALE; NUTRITIONAL STATUS; OBSERVATIONAL STUDY; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; SECONDARY HYPERPARATHYROIDISM; TREATMENT DURATION; UREMIA;

EID: 33845942705     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880602901104     Document Type: Article

References (33)

1. Zehnder C, Gutzwiller JP, Renggli K. Hemodiafiltration: A new treatment option for hyperphosphatemia in hemodialysis patient. Clin Nephrol 1999; 52: 152-9.
2. Zucchelli P, Santoro A. Inorganic phosphate removal during different dialytic procedures. Int J Artif Organs 1987; 10: 173-8.
3. Fischbach M, Hamel G, Simeoni U, Geisert J. Phosphate dialytic removal: Enhancement of phosphate cellular clearance by biofiltration (with acetate-free buffer dialysate). Nephron 1992; 62: 155-60.
4. Ratanarat R, Brendolan A, Volker G, et al. Phosphate kinetics during different dialysis modalities. Blood Purif 2005; 23: 83-90.
5. Pohlmeier R, Vienken J. Phosphate removal and hemodialysis conditions. Kidney Int Suppl 2001; 78: S190-4.
6. Minutolo R, Bellizzi V, Cioffi M, et al. Postdialytic rebound of serum phosphorus: Pathogenetic and clinical insights. J Am Soc Nephrol 2002; 13: 1046-54.
7. DeSoi CA, Umans JC. Phosphate kinetics during high-flux hemodialysis. J Am Soc Nephrol 1993; 4: 1214-8.
8. Massa P, Gropuzzo M, Cleva M, et al. Behaviour of phosphate removal with different dialysis schedules. Nephrol Dial Transplant 1998; 13 (suppl 6): S43-8.
9. Gotch FA, Froilan F, Sergeyeva O, et al. A kinetic model of inorganic phosphorus mass balance in hemodialysis therapy. Blood Purif 2003; 21: 51-7.
10. Mallamaci F, Tripepi G, Zoccali C. Leptin in end stage renal disease (ESRD): A link between fat mass, bone and the cardiovascular system. J Nephrol 2005; 4: 464-8.
11. Costantini S, Meschini R, Meschini L, et al. Hemodiafiltration with endogenous reinfusion (HFR): Biochemical and gas-analytical analysis of the "regenerated" ultrafiltrate. G Ital Nefrol 2004; 21 (Suppl 30): S75-9.
12. Kunitomo T, Lowrie EG, Kumazawa S, et al. Controlled ultrafiltration with hemodialysis: Analysis of coupling between convective and diffusive mass tansfer in a new HD-UF system. Trans Am Soc Artif Intern Organs 1977; 23: 234-43.
13. De Francisco ALM, Ghezzi PM, Brendolan A, et al. Hemodiafiltration with on line regeneration of the ultrafiltrate. Kidney Int Suppl 2000; 76: S66-71.
14. Bolasco PG, Ghezzi PM, Ferrara R, et al. New method for the phosphate kinetics estimation during hemodialysis and on-line hemodiafiltration with endogenous reinfusion (HFR). Blood Purif 2006; 24: 301-8.
15. Panichi V, Manca-Rizza G, Paletti S, et al. Effects on inflammatory and nutritional markers of haemodiafiltration with online regeneration of ultrafiltrate (HFR) vs on line haemodiafiltration: A cross-over randomized multicentre trial. Nephrol Dial Transplant 2006; 21: 756-62.
16. National Kidney Foundation. K/DOQI Clinical Practice guidelines: Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42 (Suppl 4): S11-2011.
17. Faugere MC, Gao P, Genz Z, Cantor TL, Malluche HH. The 1-84:7-84 ratio for determination of bone turnover in chronically dialyzed patients. Abstract of Annual American Society Toronto. J Am Soc Nephrol 2000; 11: 554A.
18. Malluche HH, Monier-Faugere MC. PTH 1-84, PTH fragments and bone turnover. Am J Kidney Dis 2003; 41: 1127.
19. Lehmann G, Stein G, Huller M, et al. Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry. Kidney Int 2005; 68: 1206-14.
20. Flanigan MJ, Fangman J, Lim VS. Quantitating hemodialysis: A comparison of three kinetic models. Am J Kidney Dis 1991; 17: 295-302.
21. Delmez JA, Slatopolsky E. Hyperphosphatemia: Its consequences and treatment in patient with chronic renal disease. Am J Kidney Dis 1992; 19: 303-17.
22. Alfrey AC. The role of abnormal phosphorus metabolism in the progression of chronic kidney disease and metastatic calcification. Kidney Int Suppl 2004; 90: S13-7.
23. Hsu CH. Are we mismanaging calcium and phosphate metabolism in renal failure? Am J Kidney Dis 1997; 29: 641-9.
24. Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patient: A national study. Am J Kidney Dis 1998; 31: 607-17.
25. Block G. How should hyperphosphatemia be managed in dialysis patients? Semin Dial 2002; 15: 315-7.
26. Spalding EM, Chamney PW, Farrington K. Phosphate kinetics during hemodialysis: Evidence for biphasic regulation. Kidney Int 2002; 61: 655-67.
27. Pogglitsch H, Estelberger W, Petek W, et al. Relationship between generation and plasma concentration of inorganic phosphorus. In vivo studies on dialysis patients and in vitro studies on erythrocytes. Int J Artif Organs 1989; 12: 524-32.
28. De Francisco ALM, Pinera C, Heras M, et al. Hemodiafiltration with on-line endogenous reinfusion. Blood Purif 2000; 18: 231-6.
29. De Francisco ALM, Botella J, Escallada R, et al. Hemodiafiltration with sorbent-regenerated ultrafiltrate as replacement fluid: A multicenter study. Nephrol Dial Transplant 1997; 12: 528-34.
30. Schindler R. Elimination of cytokines from plasma by ultrafiltration using conventional polysulfone or Diapes membranes. Contrib Nephrol 2003; 138: 37-42.
31. Cole L, Bellomo R, Davenport P, et al. The effect of couplet hemofiltration and adsorption on inflammatory cytokines in an ex vivo model. Nephrol Dial Transplant 2002; 17: 1950-6.
32. Girndt M, Kohler H. Interleukin-10 (IL-10): An update on its relevance for cardiovascular risk. Nephrol Dial Transplant 2003; 18: 1976-9.
33. Sonikian MA, Pani IT, Iliopoulos AN, et al. Metabolic acidosis aggravation and hyperkaliemia in hemodialysis patients treated by sevelamer hydrochloride. Ren Fail 2005; 27: 143-7.